Brief: Aravive - Avb-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab Or Parp Inhibitor Olaparib For Uterine Cancer
30/03/2020 15:27
March 30 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE ANNOUNCES AVB-500 IMPROVES ANTI-TUMOR EFFECTS WHEN
COMBINED WITH ANTI-ANGIOGENIC BEVACIZUMAB OR PARP INHIBITOR
OLAPARIB IN PRECLINICAL MODELS OF UTERINE CANCER
Source text for Eikon: ID:nGNX1Dg3Lw
Further company coverage: ARAV.O
((Briefs@thomsonreuters.com;))